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Patients with increased ExBP showed significantly higher (~~0.05 - 0.001) Idl-cholesterol 
and triglyceride levels and significantly lower hdl-cholesterol levels. 
Conclusions: Despite normotensive BP during ABPM. obese patients frequently show a 
pathologically increased BP response during standardized ergometry. This increased BP 
response to exercise has an influence not only on LVMI, but also on cardiovascular mor- 
tality, and should therefore be assessed in obese patients. 
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1032-120 Expression of NAD(P)H Oxidase Components in Human 
Platelets 
Naglaa A. ECSherbeeny, Lawrence T. McGrath. Lana J. Dixon, Siobhan Brennan, @y 
E. McVeiah Queen’s University Belfast, Belfast, United Kingdom 
Background. Nitric oxide (NO) is involved in vasodilation. This is related to the bioavail- 
ability of NO, rather than absolute production. A major scavenger of NO is the superoxide 
anion which is released by endothelial and vascular smooth muscle cells. Platelets 
release both NO and superoxide and share many pathways found in endothelial cells. 
We examined human platelets for components of of the superoxide generating system, 
NAD(P)H oxidase. Methods. Platelets and leukocytes were prepared by sequential cen- 
trifugation and lysed in buffer containing n-octyl-D-glucopyranoside (ODG). Early pas- 
sage human aortic endothelial cells (HAECs) were cultured until confluence, washed and 
lysed in ODG containing buffer. Standardised amounts of each lysed cell type were anal- 
ysed by SDS-PAGE and Western blotting using anti gp 91 phox and anti racl primary 
antibodies and visualised by enhanced chemiluminescence. Results. We demonstrated 
gp 91 phox and RX 1 in human platelets in amounts equal to or greater than that found 
in cultured human HAECs. These componets of NAD(P)H oxidase were found in all sam- 
ples of platelets examined (n=lO). Conclusion. Other workers have demonstrated the 
am- 
ma- 
presence of p22 phox and ~67 phox which along with our observations comprise the 
major components of NAD(P)H oxidase found in human endothelial cells. We suggest 
this makes isolated platelets a suitable model to study changes in endothelial cell super- 
oxide pathway components in response to various interventions. 
1032-121 Binding of FVlla to TF Promotes Smooth Muscle Cell 
Proliferation In Vitro via Activation of the Extracellular 
Regulated Kinases 
Plinio Clnllo, Paolo Golino, Paolo Calabro, Gaetano Cali, Lavinia Forte, Salvatore De 
Rosa, Mario Pacileo, Francesco Scopacasa. Massimo Chiariello, University of Naples, 
Naples, Italy, 2nd University of Naples, Naples, Italy 
&stenosis following PTCA recognizes smooth muscle cell (SMC) prokferation as a key 
event. However, the mechanisms involved are not completely known. Tissue Factor (TF), 
a transmembrane glycoprotem. forms a complex with factor VII (FVII), thus activating the 
coagulation pathway. However, TF may function also es a membrane receptor and we 
have previously shown that binding of activated FVII (FVlla) to TF induces SMC prolifer- 
ation. In the present study we assessed whether this phenomenon is the result of activa- 
tion of the extracellular signal regulated kinase (ERK) pathway. SMCs from rabbit aortas 
were made quiescent by serum deprivation. After 24 hrs, SMCs were stimulated with 
FVlla (100nM) and orocessed for total orotein isolation at baseline (no stimulation). and ,. 
after 1, 2, 5, 15. 20. 30 and 60 min following stimulation. Phosphorylation (activation) of 
ERKs (oERKs) was assessed bv immunoblottina usino anti-oERK antibodv. To better _ _ 
define the role of PERK in SMC proliferation, in additional experiments, SMCs were pre- 
incubated with UO126 (IOpM), an inhibitor of ERK phosphorylation; SMCs were stimu- 
lated with FVlla as above and proliferation (thymidine incorporation) and ERK 
phosphorilation (immunoblotting) evaluated. SMC proliferation appeared to be related to 
ERK activation. as suggested by the observation that UO126 inhibited it. This effect was 
associated with the inhibition (delay) of ERK phosphorilation. Thus, TF/FVlla complex 
leads to SMC proliferation via activation of ERKs. 
KKK - PlroMlbaciblni 
ep*- 
1032-l 22 The Molecular Mechanisms of Calcium Dependent 
Tissue-Type Plasminogen Activator Release 
James A. Muldownev. Ill, Corrie A. Palmer, Elaine Sanders-Bush, Nancy J. Brown. 
Douglas E. Vaughan, Vanderbilt University Medical Center, Nashville, TN 
Physiologic release of tissue-type plasminogen activator (t-PA) from the endothelium is 
critical for vascular homeostesis. Atherosclerosis and cigarette smoking impair coronary 
release of t-PA. Thrombin-induced t-PA release is a g-protein coupled, calcium-depen- 
dent phenomenon. S is the g-protein primarily responsible for GPCR-dependent csl- 
cium signaling. In this study, we tested the hypothesis that thrombin-induced t-PA 
release is a $, phospholipase-CD (PLCp), and inositol-triphosphate (IP&dependent 
phenomenon. Human microvascular endothelial cells were incubated with2mM sodium 
butyrate for 24 hours. Cells were washed and incubated for 30 minutes in Ml99+0.03% 
albumin and inhibitors in triplicate. Cells were stimulated with 10 U/ml thrombin, agonist, 
or vehicle. Medium was harvested at 0 and 5 minutes, and t-PA antigen was measured 
by ELISA. Cells were pretreated with a decoy peptide identical to the $ c-terminus 
linked to a membrane permeable sequence (MPS-Gd prior to thrombin treatment. A 
peptide containing the 4 sequence was a negative control (MPS-&). Separately, cells 
were stimulated with Pasteurella multocidia toxin (rPMT), a G, agonist. MPS-G, obliter- 
ated thrombin induced t-PA release while MPS-C, did not. Treatment with rPMT, trended 
towards induction of t-PA release at 140 pM. Thrombin-induced t-PA release was inhib- 
ited in a dose-dependent manner by U73122, a PLCQ antagonist (lC,=@M). U73343, 
an inert analog, had no effect. The I& receptor antagonist P-APB also inhibited throm- 
bin-induced t-PA release in a dose-dependent manner (IC&+OpM). Thrombin-induced 
t-PA release in human endothelial cells is $, PLCp. and IPs-dependent. Acquired 
impairment of coronary t-PA release in smokers may involve alterations in one or more 
messengers in this pathway, which may partially explain the increased risk of coronary 
thrombosis in these groups. 
1032-123 Altered Balance of Matrix Metalloproteinase and Tissue 
Inhibitor of Metalloproteinase in Human Atherosclerotic 
Plaque: Evidence From Quantitative Analysis of Gene 
Expression Using Real-Time FIT-PCR Method 
Takeo Hiaashikata, Masakezu Yamagishi. Toshio Higashi, lzumi Nagata, Aiji Sakamoto, 
National Cardiovascular Center Research Institute. Suita, Japan, National 
Cardiovascular Center, Suita. Japan 
Background: Although gene expression survey for atherosclerotic lesion has been 
recently conducted by cDNA array, few data exist regarding quantitative measurement of 
key genes in human atherosclerotic tissue. We developed an efficient procedure that 
makes it possible to quantitate expression levels of various genes in the scarce amount 
of human tissue available. And we tested a hypothesis that altered expression balance of 
matrix metalloproteinases (MMPs) to tissue inhibitors of metalloproteinase (TIMPs) plays 
a pivotal pathogenetical role in human atherosclerosis. 
Methods: Samples of the plaque shoulder region and minimally affected intima were 
obtained from atherosclerotic carotid arteries in 24 patients with carotid endoatterec- 
tomy. Total RNA was extracted from the samples and subjected to cDNA synthesis with 
random primer. Amount of the cDNAs for MMP-I, 2, 3 and 9. and TIMP-I, 2, 3 and 4 in 
each cDNA mixture were determined by real-time RT-PCR method using ABI 7700 
sequence detection system (Appliedbiosystams), and normalized with that of GAPDH 
(glutsraldehyde 3-dehydrogenase) as a reference gene. 
Results: Total RNA (0.49*0.22pg) was successfully extracted from small amount of the 
human samples weighing 11.7*2.64mg, which was adequate for cDNA synthesis. In 
shoulder region, the genes for MMP-1 (1.27+~0.27) and MMP-9 (2.2OkO.55) were signifi- 
cantly augmented than those in minimally affected intima (0.30~0.12 and 0.62+0.24. 
respectively, pcO.01). Also, the expression levels of TIMP-1 and TIMP-3 genes were 
higher in shoulder region (1.22*0.22 vs. 0.61+0.47, and 0.47r0.12 vs. 0.26*0.09, 
respectively). The indices of MMP-ITTIMP-1 and MMP-S/TIMP-1 were 2.6 and 4.5 times 
higher in plaque shoulder region than in minimally affected intima. 
Conclusion: Upregulation of MMPs in plaque shoulder region was disproportional to that 
of TIMPs, suggesting that active degradation of extracellular matrix persists in advanced 
atherosclerotic lesion. We consider that quanbtative measurement of gene expression 
with the present method in human atherosclerotic tissue gives us deep understanding for 
its pathogeneses. 
1032-124 Fibrinolytic Activity and Protein Gene Polymorphisms: 
Association With Coronary Artery Disease 
Raymond L. Benz+. University of Alabama at Birmingham, Birmingham, AL 
Background: Impaired fibrinolytic activity (FA) is associated with atherosclerosis and 
may be determined, in part, by specific fibrinolytic protein (FP) gene polymorphisms 
(PM@, yet interrelationships between these PMs, Fas , and clinical atherosclerosis 
remain unclear. We determined whether associations existed between FP gene PMs, FP 
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expression, FA, and the presence and/or severity of Coronary Artery Disease (CAD). 
Methods: Patients, prospectively enrolled, had blood drawn and analyzed for: gene PMs 
(PCRIRFLP: t-PA. Alu repeat; urokinase, BamHI; PAI-1, Hindlll; fibrinogen, Haelll; 
MTHFR, Hinfl). plasma levels of FPs (ELISA: t-PA, PAI-1, u-PA). fibrinogen (clotting 
assay), FA (PAP assay), Lp(a) and homocysteine. The absence/presence and severity of 
CAD was determined by angiographic analyses; medical histories included risk factors. 
Data were analyzed by logistic regression, multivariate analysis and combined risk factor 
interactions. _ 
Results: Of the 1107 patients enrolled (57% male, 70% Caucasian, age 19.88 yrs), 465 
(21%) had no CAD. Factors associated with CAD presence were: U-PA PM, age, smok- 
ing, Lp(a), hypercholesterolemia. PAI- activity/antigen and a combined U-PA and fibrin- 
ogen PM interaction and gender/age interaction. Factors associated with CAD severity 
were: U-PA PM, age, smoking, hypercholesterolemla, diabetes, BMI, t-PA antigen. Lp(a) 
and a combined u-PA and fibrinogen PM interactton, u-PA and t-PA PM interaction, u-PA 
and MTHFR PM interaction and a gender/race Interaction. The u-PA PM, independently 
and/or in association with other FP PMs. was associated with plasma levels of FA, PAI- 
antigen/activity and fibrinogen, but not u-PA.Conclusions: 1) The u-PA PM appears to 
be associated with the development and progression of CAD; 2) A significant interaction 
exists between various FP PMs, particularly the u-PA PM, in determining plasma FP lev- 
els and FA; 3) Lack of association between the u-PA PM and plasma u-PA levels sug- 
gests that regulation of plaque-localized expression of u-PA is important. These results 
suggest a potential role for FPsiFA and FP gene interactions in the development and 
progression of CAD with age. 
1032-l 25 Plasma PAI- Antigen Concentration Predicts Clinical 
Outcome of Thrombolytic Treatment of Acute 
Myocardial Infarction 
Aaata Mlvnarska, Tomasz Waszyrowski, Jaroslaw D. Kasprzak, Jonscher Hospital. 
Lodz, Poland, Institute of Internal Medicine, Medical University of Lodz, Lodz, Poland 
Background: Plasmlnogen activators inhibitor type 1 (PAI-1) is the most important regula- 
tory element in fibnnolytic system, and may be involved in the efficacy of fibrinolytic treat- 
ment for acute myocardial infarction (AMI). 
Aim: The study aimed lo elucidate the association between plasma PAI- antigen con- 
centration (PAS) and activity (PAct) before and after standard streptokinase (STK) infu- 
sion and clinical outcome in patients (pts) with AMI. 
Material and methods: The studied group consisted of 82 pts with AMI with ST elevation 
(aged 61.0+9.0 yrs. 26 females, 56 males) treated with STK. Plasma PAg and PAct were 
measured before, immediately after and 1,2,3,4,5 hours after STK infusion using com- 
mercially available ELISA tests (Biopool, Sweden). Clinical outcome (mortality, reperiu- 
slon and reocclusion rate) was analyzed during mean follow-up of 59 weeks (range I- 
96). Kaplan-Meier curves for overall survival (OS) and event-free survival (EFS) were 
calculated according to PAg concentration. 
Resulb: Peak increase in PAg and PAct was demonstrated after STK treatment in the 
3rd hour. Therefore, PAg and PAct at admission to hospital (PAgO. PActO) and 3 hours 
after STK (PAg3, PAct3) were further analyzed. PAg3 and PAct3 were significantly 
higher as compared to PAgO and PActO (30.0+13.3 vs. 20.8i8.6 ng/ml, p=O.O01 and 
37.3+13.7 vs. 10.0*11.2 IU/ml, p<O.OOOl, respectively). PAg3 values were increased in 
pts who died during follow-up (n=l5)(40.8*3.3 vs. 24.7i14.2 ng/ml, p=O.O38) and in pts 
without reperfuslon (36.5tll.4 vs. 20.3r12.6 @ml, p=O.O29). Threshold value of PAg3 
predictive for no repedusion, calculated using ROC curve analysis, were 21.8 ng/ml 
(sew. 77%, spec. 59%, area under the ROC curve 0.65) and for fatal outcome 33.3 ngl 
ml @ens. 90%, spec. 66%, area under the ROC curve 0.70). The probability of survival of 
pts with PAg3 over and below 33.3 ng/ml was 65% and 97% respectively (p=O.O0016). 
There was no significant difference in PActO and PAcl3 between groups separated con- 
cerning mortality, repedusion and reocclusion. 
Conclusions: Plasma PAI- antigen concentration over 33.3 nglml in the 3rd hour after 
fibrinolytlc treatment of AMI predicts unfavorable clinical outcome. 
1032-I 26 Thrombin Potentiates Platelet-Derived Growth Factor 
Induced Vascular Smooth Muscle Cell Proliferation via 
PI3 Kinase Activation and p27 Downregulation 
Karin Frischknecht Helen Greutert, Thierry P. Carrel, F&x C. Tanner, Untversity 
Hospital Bern, Bern, Switzerland 
Thrombus formation and vascular smooth muscle cell (VSMC) proliferation are key 
events in the pathogenws of vascular diseases. Mediators from both platelets such as 
PDGF and the coagulation system such as thrombin can affect VSMC proliferation. 
Thus, we examined whether PDGF and thrombin interact at the level of VSM cell cycle 
regulation. When human saphenous vein VSMC were stimulated with a maximal concen- 
tration of thrombin (3 U/ml), no significant increase !n cell number was observed over 4 
days. In contrast, thrombin potentlated threshold concentrations of PDGF-BB (1 nglml) 
(increase in cell number: thrombin alone 4’375&‘105; PDGF alone 5’375i2’057; throm- 
bin plus PDGF 18‘688~1’711; p=n.s. for thrombin vs. PDGF; pcO.0002 for thrombin or 
PDGF vs. thrombln plus PDGF; n=4). SH-thymidine incorporation revealed that potentia- 
tion did also occur with ten times lower thrombin concentrations (n=6). Potentiation was 
prevented by hirudin (3 U/ml). Thrombin did not alter PDGF c( or p receptor expression 
as determined by FACS analysis. Thus, expression of cell cycle proteins regulating Gl 
progression was determined by Western blotting for up to 30 hours of mitogenlc stimula- 
tion. The cyclin-dependent kinase inhibitors ~21, ~27, and p57 were neither affected by 
thrombln nor PDGF alone. In contrast, thrombin plus PDGF caused p27 downregulatlon, 
while ~21 was slightly Induced. and p57 remained unaffected. Expression of cyclin- 
dependent kinase 2 (cdk2) and cyclln E was not affected under all these conditions. 
CdkP activity was neither affected by thrombin nor PDGF alone, but enhanced by throm- 
bin plus PDGF. This increase in cdk2 activity was prevented by hirudin. Inhibition of PI3 
kinase by LY294002 prevented p27 downregulatlon In response lo thrombin plus PDGF. 
Thrombin alone did not activate AkVPKB, while activation by PDGF alone was identical 
to that by PDGF plus thrombin. Thus, thrombin IS not mitogenlc for human saphenous 
vein VSMC, but strongly potentiates VSMC proliferation to PDGF in a dose-dependent 
manner. This potentiation is related to activation of PI3 kinase, and results in Akt/PKB 
independent downregulation of the CKI ~27. 
1032-127 Tissue Factor Pathway in Carotid Atherosclerotic 
Plaques: Relationships With Clinical Patterns and Risk 
Factors 
Christophe Zawadzki, Stephan Haulon, Sophie Susen, Andre Vincentelli, Emmanuelle 
Jeanpierre, Christian Lucas, Enc Van Belle, Florence Richard, Delphine Corseaux, 
Brigitte Jude, HBpital Cardiologique, Lille, France, lnstitut Pasteur. Lille, France 
Background: Tissue Factor (TF) and its inhibitor, the tissue factor pathway inhibitor 
(TFPI) probably play an Important role in the thrombogenicity of atherosclerotic plaques 
but the factors regulating their expression are poorly known. 
Methods TF,TFPI and activated factor VII (F Vlla) levels were measured in the athero- 
sclerotic plaques of 100 consecutive patients undergoing carotid endartereclomy. A mul- 
tiple linear regression model was used lo test the relationships between TF, TFPI and 
FVlla with 1) documented history of ischemic cerebral events (ICE), 2) conventional car- 
diovascular risk factors, 3) markers of inflammation (fibrinogen, interleukin-6, CRP) and 
coagulation activation (thrbmbin-antithrombin complexes, D-dimers) and metabolic syn- 
drom (Body mass index (BMI), insulinemia, triglyceridemia) and 4) plaque morphology 
(presence or absence of a massive lipid-rich core). 
Results : Plaque TF activity. TFPI antigen and FVlla were strongly correlated with each 
other. TF and TFPI but not FVlla were higher in the 40 symptomatic than In the 60 
asymptomatic patients (TF :1.82*0.32 vs 1.02*0.29 mlfigramme of plaque, median+ 
[95%CI]., p=O.O08 and TFPI :53.50*11.36 vs 20.6Oi7.92 pg/g, p=O.OOOl, respectively). 
The distribution of traditional cardiovascular risk factors was not different between 
asymptomatic and symptomatic subjects. TF activity was higher and TFPI was lower in 
men than in women. The plasma CRP level was a strong independent predictor for 
plaque TF activity. BM1>25 and maswe lipid rich core were positive predictors and 
hypertriglyceridemia was negative predictors for plaque TFPI. 
Conclusion : In carotid plaques, TF and TFPI levels were higher In patlents with a docu- 
mented history of ICE. TF is strongly related to the inflammatory process while TFPI is 
dependent of the presence of a massive lipid core and of markers of the metabolic syn- 
dram. 
1032-l 28 Novel Role for the Membrane-Bound Chemokine 
Fractalkine: A Pathophysiologlcally Relevant 
Mechanism in Platelet Activation and Adhesion 
Andreas Schaefer, ChristIan Schulz, Martin Eigenthaler, Daniela Fraccarollo, Meinrad 
Gawaz, Georg Ertl, Ulrich Walter, Johann Bauersachs, Medizinische Universltaetsklinik 
Wuerzburg, Wuerzburg, Germany, Deutsches Herzzentrum Muenchen, Munich, 
Germany 
Background: Chemokines released by the endothelium have pro-aggregatory properties 
on platelets. Fractalkine, a recently dwovered membrane-bound chemokine with a 
transmembrane domain, is expressed in vascular injury, however, the effects of fractalk- 
Ine on platelets have not yet been investigated. 
Methods and Results: Blood was taken from healthy Wistar-Kyoto-rats and the expres- 
slon of the fractalkine-receptor on platelets was demonstrated. The modulation of sur- 
face-expression of P-selectin, a reliable marker of platelet activation, was assessed by 
flow cytometry. P-selectin expression was significantly enhanced by in vitro stimulation 
with recombinant rat fractalkine (FR: 60.4i7.7 mfu [mean fluorescence units]) as com- 
pared with baseline levels (BL: 21.6*2.9 mfu. p<O.OOl). Preincubation with either the 
nitric oxide-donor sodium nitroprusside (SNP) or the cyclooxygenase inhibitor acetyl sail- 
cylic acid (ASA) prevented the fractalkine-induced Increase in surface P-seledin expres- 
sion. Selectively inhibiting the function of recombinant fractalkine by an antagonizing 
antibody (anti-FR) or the dlsruption of the G-protein coupled intracellular signaling cas- 
cade of the fractalkine receptor by pertussis toxin (PTX) completely prevented fractalkine 
mediated platelet activation and adhesion (antl-FR: 15.2eO.9 mfu; PTX: 19.8e3.1 mfu, 
p<O.OOl vs. FR). 
In an adhesion flow chamber stimulation wth fractalkine significantly enhanced platelet 
adhesion to collagen and fibrinogen by 20% and 60% respectively. Similar to P-selectin 
expression, enhanced adhesion could be prevented by the antagonizing antibody or pre- 
incubation of platelets with PTX. 
Conclusion: The membrane-bound chemokine Induces platelet activation and adhesion. 
As fractalkine is overexpressed in atherosclerosis and vascular injury it IS likely to sub- 
stantially contribute to increased thrombogenesis in vascular diseases. 
1032-l 29 Mineralocorticoid Receptor Antagonism Attenuates 
Thrombotic Response to Injury in Atherosclerosis 
Through Favorable Effects on Nitric Oxide 
Bioavailability 
Saniav Raiaaopalan, Peter Bodary, Damon Duquaine, Bertram Pitt, Dame1 Eitzman, 
University of Michigan, Ann Arbor, Ml 
Background: Recent studies have demonstrated favorable effects of mlneralocorticoid 
receptor (MR) blockade in conditions associated with up-regulation of the renln-angio- 
tensin axls. We hypothesized that spironolactone modulates thrombotlc response to 
injuly in a genetlc model of hyperlipidemia. 
Methods: LDL receptor knock out mice (LDLR-‘-) were implanted with spironolactone (35 
mgJkg/day) or placebo pellets at 6 weeks while on high lipid chow (5-8 animals/group). At 
18 weeks, vasomotor responses were assessed in aortas, with measurement of time to 
thrombosis after photochemical carotid artery injury. Aldosterone infused animals served 
